ScripWhile 2023 saw several cell and gene therapy approvals that were genuine scientific and clinical breakthroughs, many smaller companies in the sector bore the brunt of the ongoing biopharma downturn. M
ScripPyxis Oncology , Theseus Pharmaceuticals, Inc. and Cognition Therapeutics, Inc. launched initial public offerings in the US between 6 and 8 October, raising $373.2m combined, but the first three c